KaloBios Appoints V. Bryan Lawlis, Jr., Ph.D. to Board of Directors

     KaloBios Appoints V. Bryan Lawlis, Jr., Ph.D. to Board of Directors

PR Newswire

SOUTH SAN FRANCISCO, Calif., Aug. 7, 2013

SOUTH SAN FRANCISCO, Calif., Aug. 7, 2013 /PRNewswire/ -- KaloBios
Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of V.
Bryan Lawlis, Jr., Ph.D. to the KaloBios Board of Directors. Dr. Lawlis is
President and Chief Executive Officer of Itero Biopharmaceuticals, LLC and
also serves as a Director of Biomarin Pharmaceutical, Geron, and Sutro
Biopharmaceuticals. Dr. Lawlis replaces former KaloBios Director Brigitte
Smith, co-founder and Managing Partner of GBS Ventures.

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

"Bryan Lawlis is a veteran of the biotechnology industry, with over 30 years
experience in the development, manufacture and commercialization of
biologics," said David Pritchard, KaloBios President and Chief Executive
Officer. "His extensive industry knowledge and drug development experience,
especially in the manufacturing of therapeutic proteins and antibodies, will
serve KaloBios well as we advance the development of our portfolio of
proprietary, patient-targeted, monoclonal antibodies towards
commercialization."

"We also thank Brigitte Smith for her 10 years of valuable service to KaloBios
as a board member during an important phase of our company's development and
growth," said Mr. Pritchard.

Dr. Lawlis co-founded Itero Biopharmaceuticals, a privately held developer of
value-added follow-on and novel therapeutic proteins and antibodies, in 2006.
Prior to that, Dr. Lawlis served as President and Chief Executive Officer of
Aradigm Corporation fromAugust 2004, and served on its Board of Directors
fromFebruary 2005, continuing in both capacities untilAugust 2006. Dr.
Lawlis served as Aradigm Corporation's President and Chief Operating Officer
fromJune 2003toAugust 2004, and that company's Chief Operating Officer
fromNovember 2001toJune 2003. Previously, Dr. Lawlis co-founded Covance
Biotechnology Services, a contract biopharmaceutical manufacturing operation,
served as its President and Chief Executive Officer from 1996 to 1999, and
served as Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc.,
a division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was employed at
Genencor, Inc. and Genentech, Inc. His last position at Genentech was Vice
President of Process Sciences. Dr. Lawlis holds a B.A. in microbiology from
theUniversity of Texas at Austinand a Ph.D. in Biochemistry fromWashington
State University.

About KaloBios

KaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary,
patient-targeted, first-in-class monoclonal antibodies designed to treat
severe life-threatening or debilitating diseases for which there is an unmet
medical need, with a clinical focus on severe respiratory diseases and cancer.

Currently, KaloBios has three drug development programs:

  oKB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases,
    is being developed for the treatment of severe asthma. Enrollment of 160
    patients has been completed in a planned 150 patient Phase 2 study in the
    United States, Europe and Australia.
  oKB001-A, an anti-PcrV mAb fragment, is partnered exclusively with Sanofi
    and is being developed for the prevention and treatment of Pa infection.
    KaloBios has retained rights for the CF indication and has initiated a 180
    patient Phase 2 study in CF subjects with chronic Pa lung infection in the
    United States. Sanofi is pursuing a ventilator associated pneumonia
    prevention indication in the intensive care setting, an indication which
    has received U.S. FDA Fast Track Designation.
  oKB004, an anti-EphA3 mAb, has potential in treating hematologic
    malignancies and solid tumors. KaloBios is currently testing this drug in
    a Phase 1 study in subjects with hematologic malignancies.

All of the company's antibodies were generated using its proprietary
Humaneered^® technology, a method that converts nonhuman antibodies (typically
mouse) into recombinant antibodies that have a high binding affinity to their
target and are designed for chronic therapeutic use. The company believes that
antibodies produced using its Humaneered^® technology offer important clinical
and economic advantages over antibodies generated by other methods in terms of
high binding affinity, high manufacturing yields, and minimal to no
immunogenicity (inappropriate immune response) upon repeat administration in
humans.

For more information on KaloBios Pharmaceuticals, please visit our web site at
http://www.kalobios.com.

Forward Looking Statements
This release contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995,
including statements regarding the company's clinical development of KB001-A,
KB003 and KB004. Forward-looking statements reflect management's current
knowledge, assumptions, judgment and expectations regarding future performance
or events. Although management believes that the expectations reflected in
such statements are reasonable, they give no assurance that such expectations
will prove to be correct and you should be aware that actual results could
differ materially from those contained in the forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties
including, but not limited to, the company's limited cash reserves and its
ability to obtain additional capital on acceptable terms, or at all, including
the additional capital which will be necessary to complete the clinical trials
that the company has initiated or plans to initiate; the company's dependence
on Sanofi Pasteur for the development and commercialization of KB001-A; the
company's ability to successfully complete further development of its
programs; the uncertainties inherent in clinical testing; the timing, cost and
uncertainty of obtaining regulatory approvals; the company's ability to
protect its intellectual property; competition; changes in the regulatory
landscape or the imposition of regulations that affect the company's products;
the company's ability to attract and retain key personnel; and other factors
listed under "Risk Factors" in the company's Annual Report on Form 10-K filed
with the Securities and Exchange Commission on April 1, 2013, the quarterly
report on Form 10-Q filed on May 14, 2013 and the company's other filings with
the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by
this cautionary notice. You are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this release.
The company has no obligation, and expressly disclaims any obligation to
update, revise or correct any of the forward-looking statements, whether as a
result of new information, future events or otherwise.

Contact:
Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
(650) 243-3146
ir@kalobios.com

Media Contact:
Joan E. Kureczka
Kureczka/Martin Associates
Tel: (415) 821-2413
Mobile: (415) 690-0210
Joan@Kureczka-Martin.com

SOURCE KaloBios Pharmaceuticals, Inc.

Website: http://www.kalobios.com
 
Press spacebar to pause and continue. Press esc to stop.